Lenvatinib: first global approval

Drugs
Lesley J Scott

Abstract

Lenvatinib (Lenvima™) is a multitargeted receptor kinase inhibitor that inhibits the kinase activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth factor receptors 1, 2, 3 and 4, platelet-derived growth factor receptor α, RET and KIT. In addition to their role in normal cellular function, these kinases have been implicated in pathogenic angiogenesis, tumour growth and cancer progression. Lenvatinib is being developed by Eisai Co. Ltd for the treatment of solid tumours, primarily for differentiated thyroid cancer, and other malignancies. A capsule formulation of the drug has received approval in the USA for use in locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Lenvatinib is in pre-registration for this indication in the EU, Australia, Brazil, Canada, Japan, South Korea, Russia, Singapore and Switzerland, and is in phase 3 development in Argentina, Chile and Thailand. Lenvatinib has orphan designation in the EU and Japan for use in differentiated thyroid cancer. In addition, an ongoing global, phase 3 trial is evaluating the use of lenvatinib as first-line treatment in unresectable hepatocellular carcinoma. This article summarize...Continue Reading

References

Jan 13, 2011·International Journal of Cancer. Journal International Du Cancer·Skjalg BruheimØystein Fodstad
Mar 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kazuhiko YamadaTomohide Tamura
Feb 20, 2014·International Journal of Clinical Pharmacology and Therapeutics·Robert ShumakerKun Chen
Mar 25, 2014·Cancer Chemotherapy and Pharmacology·Robert C ShumakerBorje Darpo
Jun 27, 2014·European Journal of Dentistry·Francesca Maria Giovanna PiliValentino Garau
Jul 16, 2014·Clinical Drug Investigation·Robert C ShumakerMin Ren
Sep 11, 2014·Journal of Clinical Pharmacology·Robert ShumakerMin Ren
Nov 5, 2014·Therapeutic Advances in Medical Oncology·Francis Worden
Nov 8, 2014·Investigational New Drugs·Anne-Charlotte DubbelmanJos H Beijnen
Jan 2, 2015·Therapeutic Advances in Medical Oncology·T Alonso-GordoaEnrique Grande
Jan 16, 2015·ACS Medicinal Chemistry Letters·Kiyoshi OkamotoJunji Matsui
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Nov 13, 2015·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Akihiko TsuruokaYasuhiro Funahashi

❮ Previous
Next ❯

Citations

Feb 13, 2016·Targeted Oncology·James E Frampton
Oct 31, 2017·Current Oncology Reports·Paola JimenezCamilo Jimenez
May 14, 2019·Archiv der Pharmazie·Eman E NasrMohammed A M Massoud
Apr 18, 2019·Drugs·Zaina T Al-SalamaLesley J Scott
Mar 15, 2019·Journal of Hematology & Oncology·Shuang QinKongming Wu
Nov 7, 2019·Biomolecules·Javad Sharifi-RadWilliam C Cho
Oct 24, 2017·The Kurume Medical Journal·Jun-Ichi OhkuboHideaki Suzuki
Feb 2, 2019·Current Vascular Pharmacology·Cecilie BudolfsenNils Erik Magnusson
Nov 18, 2019·Advanced Drug Delivery Reviews·Xiaozhong HuangHanry Yu
Nov 3, 2020·Expert Review of Gastroenterology & Hepatology·Hui Li
Apr 27, 2021·Frontiers in Oncology·Kamila KitowskaRafal Sadej
May 5, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaume CapdevilaToni Ibrahim
May 22, 2021·Toxicology and Applied Pharmacology·Aysenur Gunaydin AkyildizBuket Alpertunga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.